208 results on '"Thuerlimann B"'
Search Results
2. Genomic characterisation of hormone receptor-positive breast cancer arising in very young women
3. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
4. Identifying oncogenic drivers associated with increased risk of late distant recurrence in postmenopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study
5. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
6. Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99
7. Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
8. Plane Stress, Plate and Shell Elements
9. Additional Considerations for the Development of Stress Fields
10. Introduction and Theoretical Basis
11. Stress Fields for Simple Structures
12. Material Strengths and other Properties
13. Treatment of breast cancer in the elderly: A prospective, population-based Swiss study
14. Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group report
15. Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials
16. Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial
17. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
18. Predictors of state-of-the-art management of early breast cancer in Switzerland
19. Small HER2-positive, node-negative breast cancer: who should receive systemic adjuvant treatment?
20. Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study
21. Geographic variation in breast cancer care in Switzerland
22. Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor for the Intensification of Cytostatic Treatment in Advanced Cancer
23. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial
24. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009
25. Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer
26. Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?
27. Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study
28. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel
29. Outlook: Computer Programs
30. Identifying oncogenic drivers associated with increased risk of late distant recurrence in postmenopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study
31. First—select the target: better choice of adjuvant treatments for breast cancer patients
32. Fatigue and menopausal symptoms in women with breast cancer undergoing hormonal cancer treatment
33. Economic analysis of terminal care for patients with malignant osteolytic bone disease and pain treated with pamidronate
34. Pamidronate treatment in patients with malignant osteolytic bone disease and pain: A prospective randomized double-blind trial
35. Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005
36. Dose-finding study of weekly docetaxel, anthracyclines plus fluoropyrimidines as first-line treatment in advanced breast cancer
37. Reply to Does the expert panel at the St Gallen meeting provide an unbiased opinion about the management of women with early breast cancer?
38. Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor
39. Bevacizumab-associated osteonecrosis of the jaw
40. Therapeutic impact of 2-[fluorine-18]fluoro-2-deoxy-D-glucose positron emission tomography in the pre- and postoperative staging of patients with clinically intermediate or high-risk breast cancer
41. Capecitabine and vinorelbine in elderly patients (≥65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99)
42. Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience
43. Present status and potential role of high-dose adjuvant chemotherapy in breast cancer with poor prognosis
44. A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis
45. Efficacy of tamoxifen following anastrozole (‘Arimidex’) compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women
46. Anastrozole (Arimidex™) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results
47. Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation
48. A randomized double-blind trial to compare the clinical efficacyof granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis
49. Comments on the St. Gallen Consensus 2003 on the Primary Therapy of Early Breast Cancer
50. Abstract P4-14-02: Analysis of DRFI and OS of HR-positive, HER2-negative breast cancer patients treated on the BIG1-98 study, classified according to a novel, integrated, clinical-pathologic and genomic classification method
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.